Vaxcyte, Inc. (NASDAQ:PCVX) Shares Acquired by Schroder Investment Management Group

Schroder Investment Management Group increased its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 211.8% during the 4th quarter, HoldingsChannel reports. The fund owned 44,818 shares of the company’s stock after acquiring an additional 30,444 shares during the quarter. Schroder Investment Management Group’s holdings in Vaxcyte were worth $3,675,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the company. Diversified Trust Co purchased a new stake in shares of Vaxcyte in the 4th quarter valued at approximately $1,433,000. China Universal Asset Management Co. Ltd. grew its position in Vaxcyte by 23.1% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 26,428 shares of the company’s stock worth $2,163,000 after acquiring an additional 4,962 shares during the period. TimesSquare Capital Management LLC increased its stake in Vaxcyte by 53.7% during the fourth quarter. TimesSquare Capital Management LLC now owns 413,637 shares of the company’s stock worth $33,860,000 after acquiring an additional 144,516 shares during the last quarter. Principal Financial Group Inc. raised its position in Vaxcyte by 186.2% in the third quarter. Principal Financial Group Inc. now owns 52,702 shares of the company’s stock valued at $6,022,000 after purchasing an additional 34,287 shares during the period. Finally, Allspring Global Investments Holdings LLC lifted its stake in shares of Vaxcyte by 70.8% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 593,523 shares of the company’s stock valued at $49,418,000 after purchasing an additional 246,049 shares during the last quarter. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on PCVX. Guggenheim reissued a “buy” rating and set a $160.00 price objective on shares of Vaxcyte in a research report on Wednesday, March 12th. Bank of America dropped their price target on shares of Vaxcyte from $157.00 to $137.00 and set a “buy” rating for the company in a research report on Tuesday, April 1st. Needham & Company LLC decreased their price objective on shares of Vaxcyte from $140.00 to $90.00 and set a “buy” rating on the stock in a report on Tuesday, April 1st. The Goldman Sachs Group dropped their target price on shares of Vaxcyte from $138.00 to $100.00 and set a “buy” rating for the company in a report on Tuesday, April 1st. Finally, Evercore ISI upgraded Vaxcyte to a “strong-buy” rating in a research note on Monday, March 31st. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $136.50.

Insider Activity at Vaxcyte

In other news, Director Teri Loxam sold 6,250 shares of the stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $85.11, for a total value of $531,937.50. Following the transaction, the director now owns 7,175 shares in the company, valued at approximately $610,664.25. This represents a 46.55 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Andrew Guggenhime sold 8,000 shares of the company’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $86.51, for a total transaction of $692,080.00. Following the completion of the transaction, the chief financial officer now owns 109,491 shares of the company’s stock, valued at approximately $9,472,066.41. The trade was a 6.81 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 38,250 shares of company stock valued at $3,170,738 over the last 90 days. 3.10% of the stock is owned by corporate insiders.

Vaxcyte Stock Up 3.4 %

NASDAQ:PCVX opened at $31.60 on Friday. Vaxcyte, Inc. has a 52 week low of $29.57 and a 52 week high of $121.06. The company has a fifty day simple moving average of $74.59 and a two-hundred day simple moving average of $89.66. The company has a market cap of $4.07 billion, a price-to-earnings ratio of -6.87 and a beta of 1.26.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($1.02) earnings per share for the quarter, topping the consensus estimate of ($1.16) by $0.14. On average, analysts expect that Vaxcyte, Inc. will post -4.21 EPS for the current year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.